Teva Pharmaceutical Industries Ltd TEVA
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is a CNS/neurology/psychiatry specialty pharmaceutical company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AUSTEDO / AUSTEDO XR | HD chorea, tardive dyskinesia | small molecule | Approved |
| AJOVY (fremanezumab) | Migraine prevention | antibody | Approved |
| UZEDY (risperidone ER injectable) | Schizophrenia; bipolar 1 | small molecule | Approved |
| COPAXONE (glatiramer acetate) | Relapsing MS | protein/peptide | Approved |
| olanzapine LAI (TEV-749) | Schizophrenia | small molecule | Phase 3 |
| Dual Action Rescue Inhaler (DARI, TEV-248) | Asthma | small molecule | Phase 3 |
| duvakitug (anti-TL1A, TEV-574; Sanofi collaboration) | Ulcerative colitis, Crohn's disease | antibody | Phase 3 |
| Proposed biosimilars to Prolia/Xgeva, Eylea, Simponi/Simponi Aria | Various | antibody | Phase 3 |
| emrusolmin (TEV-286; Modag collaboration) | Multiple system atrophy | small molecule | Phase 2 |
| anti-IL-15 (TEV-408) | Celiac disease | antibody | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.